Profund Advisors LLC boosted its position in  Zoetis Inc. (NYSE:ZTS – Get Rating) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,910 shares of the company’s stock after purchasing an additional 1,078 shares during the period. Profund Advisors LLC’s holdings in Zoetis were worth $1,892,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of  Zoetis by 0.9% during the 3rd quarter. Vanguard Group Inc. now owns 36,550,676 shares of the company’s stock valued at $5,420,101,000 after acquiring an additional 315,032 shares during the period.  State Street Corp lifted its position in shares of  Zoetis by 0.4% during the 3rd quarter. State Street Corp now owns 19,803,022 shares of the company’s stock valued at $2,936,590,000 after acquiring an additional 83,221 shares during the period.  Alliancebernstein L. P. lifted its position in shares of  Zoetis by 2.2% during the 3rd quarter. Alliancebernstein L.P. now owns 19,102,111 shares of the company’s stock valued at $2,832,652,000 after acquiring an additional 408,379 shares during the period.  Price T Rowe Associates Inc. MD lifted its position in shares of  Zoetis by 4.0% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 10,406,006 shares of the company’s stock valued at $1,548,588,000 after acquiring an additional 395,882 shares during the period.  Finally, Royal Bank of Canada lifted its position in shares of  Zoetis by 1.3% during the 3rd quarter. Royal Bank of Canada now owns 3,362,511 shares of the company’s stock valued at $498,628,000 after acquiring an additional 43,387 shares during the period. 90.23% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on ZTS shares. StockNews.com started coverage on shares of Zoetis in a research report on Thursday, March 16th. They set a “buy” rating for the company. Barclays raised their price objective on shares of Zoetis from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 21st. Finally, Bank Of America (Bofa) raised their price objective on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Nine research analysts have rated the stock with a buy rating,  According to MarketBeat.com, the company  has a consensus rating of “Buy” and an average target price of $220.43.

Shares of ZTS opened at $174.45 on Wednesday. The stock has a market cap of $80.69 billion, a price-to-earnings ratio of 38.77, a price-to-earnings-growth ratio of 2.70 and a beta of 0.77. The company has a debt-to-equity ratio of 1.49, a current ratio of 2.37 and a quick ratio of 1.63. Zoetis Inc. has a 1-year low of $124.15 and a 1-year high of $190.80. The firm has a 50 day simple moving average of $167.42 and a 200-day simple moving average of $157.12.

Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Tuesday, February 14th. The company reported $1.15 EPS for the quarter, hitting the consensus estimate of $1.15. The firm had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.01 billion. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. Zoetis’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.00 EPS.  Equities analysts forecast that  Zoetis Inc. will post 5.39 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Shareholders of record on Friday, April 21st will be paid a $0.375 dividend. The ex-dividend date of this dividend is Thursday, April 20th. This represents a $1.50 annualized dividend and a yield of 0.86%. Zoetis’s payout ratio is currently 33.33%.

Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U. S.

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.